BioSpace News Archive

CG Oncology, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and a spotlight presentation to highlight its enhanced oncology portfolio.

Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 22nd Annual Needham Healthcare Conference, being held virtually April 17-20, 2023.

Myomo, Inc. announces receipt of the final portion of the initial license fee under the Technology License Agreement with its joint venture company in China, Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the “JV Company”).

Zymeworks Inc. today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023.

Hillstream BioPharma, Inc. announced pharmacokinetic (PK) data of HSB-1216 supportive of its development strategy and pre-clinical data.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed journal, Brain Pathology.

Protect Pharmaceutical Corp. announces the completion of the recent appointment of Ali Yildiz as President and the finalization of the acquisition of Antarax Capital Danismanlik Limited.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Michael Kelly to the position of President & CEO effective April 10, 2023.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.